KCM
CHRS icon

Kennedy Capital Management’s Coherus Oncology CHRS Stock Holding History

Kennedy Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-202,506
Closed -$757K – 692
2023
Q3 		$757K Hold
202,506
– – 0.02% 588
2023
Q2 		$865K Hold
202,506
– – 0.02% 564
2023
Q1 		$1.39M Hold
202,506
– – 0.04% 448
2022
Q4 		$1.6M Sell
202,506
-30
-0% -$231 0.05% 438
2022
Q3 		$1.95M Buy
+202,536
New +$2.05M 0.06% 419
2018
Q3 		– Sell
-87,248
Closed -$1.22M – 731
2018
Q2 		$1.22M Sell
87,248
-1,432
-2% -$20.5K 0.02% 656
2018
Q1 		$980K Sell
88,680
-8,104
-8% -$88.7K 0.02% 665
2017
Q4 		$852K Sell
96,784
-1,228
-1% -$13.1K 0.02% 682
2017
Q3 		$1.31M Sell
98,012
-1,938
-2% -$25.6K 0.02% 644
2017
Q2 		$1.43M Sell
99,950
-22,944
-19% -$441K 0.03% 622
2017
Q1 		$2.6M Buy
122,894
+96
+0.1% +$2.36K 0.05% 556
2016
Q4 		$3.46M Buy
122,798
+67,969
+124% +$1.9M 0.06% 505
2016
Q3 		$1.47M Buy
+54,829
New +$1.5M 0.03% 621

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kennedy Capital Management's CHRS Position: Q4 2023 in Review

Kennedy Capital Management sold out of Coherus Oncology (CHRS) in Q4 2023, closing a stake of 202,506 shares — an estimated $757K sold.

Kennedy Capital Management first reported a position in CHRS in Q3 2016 and held it in 13 quarters. The position peaked at $3.46M in Q4 2016. 156 funds tracked by Wall St. Rank hold CHRS as of Q4 2023.

  • Kennedy Capital Management reported no remaining Coherus Oncology position as of Q4 2023 after selling out during the quarter.
  • Kennedy Capital Management sold 202,506 Coherus Oncology shares in Q4 2023, an estimated $757K.
  • Kennedy Capital Management first reported a position in Coherus Oncology in Q3 2016 and held it in 13 quarters.
  • Kennedy Capital Management's Coherus Oncology position peaked at $3.46M in Q4 2016.
  • 156 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2023.

Based on Kennedy Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.